These compounds target various signaling pathways that are involved in angiogenesis, such as vascular endothelial growth factor (VEGF) signaling, to suppress abnormal blood vessel growth and reduce the risk of diabetic retinopathy progression [94]. This evidence concerns the gene VEGFA and diabetic retinopathy.